| Autor: |
Patel K; The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK., Manzo M; Institute of Medical Genetics and Pathology, University Hospital Basel, Schönbeinstrasse 40, 4056 Basel, Switzerland., Hapuarachi B; Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Rack S; The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK., Jermann P; Institute of Medical Genetics and Pathology, University Hospital Basel, Schönbeinstrasse 40, 4056 Basel, Switzerland., Feeney L; Northern Ireland Cancer Centre, Belfast, UK., Heathcote E; The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK., Betts G; Manchester University NHS Foundation Trust, Manchester, UK., Aster JC; Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA., Murone M; Avrion Therapeutics AG, Rue de Bourg 27, 1003 Lausanne, Switzerland., Bobadilla M; Cellestia Biotech AG, Basel, Switzerland., Lehal R; Cellestia Biotech AG, Basel, Switzerland., Vogl FD; Cellestia Biotech AG, Basel, Switzerland., Harrington K; The Royal Marsden NHS Foundation Trust, Clyde Road, Wallington, London SM6, UK., Metcalf R; The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. Electronic address: robert.metcalf1@nhs.net. |
| Abstrakt: |
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships: Jon C. Aster serves on the Scientific Advisory Board of Cellestia Biotech AG., and is a consultant to Ayala Pharmaceuticals and Remix Therapeutics. Maximilien Murone is a former employee of Cellestia Biotech AG. Florian D. Vogl is a former employee of Cellestia Biotech AG. Maria Bobadilla, Raj Lehal are employees of Cellestia Biotech AG. Kevin Harrington declares honoraria (paid to his institute) from Arch Oncology, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers-Squibb, Codiak, F-Star, Merck-Serono, MSD, Pfizer, Replimune. Robert Metcalf’s conflict of interest includes Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Bayer, Achillies Therapeutics, Aptus Clinical, PCI Biotech, Ayala Pharmaceuticals and OxSonics. All other authors declare no conflict of interest. |
Full Text from ScienceDirect